Albireo Pharma appoints Streck as CMO, Hopkinson to board of directors

Albireo Pharma (ALBO) announced the appointments of two scientific leaders, Drs. Paul Streck and Craig Hopkinson, to the Enterprise Leadership Team and Board of Directors, respectively. These appointments coincide with an important time for Albireo as the Company continues to deliver on clinical, regulatory, and commercialization milestones for Bylvay for indications potentially across three pediatric cholestatic liver diseases while advancing investigational compounds for adult liver and viral diseases. As the Chief Medical Officer, CMO, Dr. Streck will join the Albireo Enterprise Leadership Team and will be responsible for providing vision, leadership, and expertise for the Company’s next growth phase, necessary to shape and enhance the CMO organization within a fully realized biopharmaceutical company. Most recently, Dr. Streck served as Chief Medical Officer at Arena Pharmaceuticals. As a member of the Albireo Board of Directors, Dr. Craig Hopkinson brings more than 25 years of experience building and leading clinical development organizations and medical affairs groups. Dr. Hopkinson currently serves as Executive Vice President of Research & Development and Chief Medical Officer at Alkermes (ALKS).